GlassScriptPhysician profile
Ross Summerford
NPI 1013354521
$17,881.72
in general payments reported to CMS, 2019-2025
47 companies · $2,818 in 2025
The $2,818 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $2,457 · 2021: $3,299 · 2022: $2,678 · 2023: $3,070 · 2024: $2,590 · 2025: $2,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,477.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,082.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,956.12 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,536.25 | 2019-2025 | |
| Lilly USA, LLC | $1,497.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,371.81 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,317.75 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $1,142.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $955.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $917.54 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $740.34 | 2019-2022 | |
| Exact Sciences Corporation | $431.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $429.70 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $427.36 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.04 | 2020-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $385.55 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Summerford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.